Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of California, San Francisco |
---|---|
Information provided by: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00187577 |
This is a single center, randomized, investigator-masked study to determine the efficacy and safety of latanaprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients who have lost their eyelashes due to alopecia areata. These medications are FDA-approved as eyedrops for patients with glaucoma who have been noted to grow longer, darker, and thicker eyelashes with their use. In this study, patients will be asked to apply these solutions to the affected eyelid margins of one eye with a sterile cotton-tipped applicator once a day.
Condition | Intervention |
---|---|
Alopecia Areata |
Drug: Latanoprost (Xalatan) Drug: Bimatoprost (Lumigan) |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Dose Comparison, Parallel Assignment, Efficacy Study |
Official Title: | Efficacy and Safety of Latanoprost (Xalatan) and Bimatoprost (Lumigan) Ophthalmic Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata |
Estimated Enrollment: | 20 |
Study Start Date: | June 2005 |
Estimated Study Completion Date: | March 2006 |
This is a pilot, single-center, randomized, investigator-masked study to evaluate the efficacy and safety of latanoprost (Xalatan) ophthalmic solution compared to bimatoprost (Lumigan) ophthalmic solution in patients with eyelash loss due to alopecia areata. This is a collaborative study between the Departments of Dermatology and Ophthalmology at UCSF. Patients will be randomized to receive either latanoprost or bimatoprost. Patients will be instructed to apply latanoprost or bimatoprost to the affected eyelid margins of one eye using a sterile cotton-tipped applicator once a day (similar to the application of eyeliner). The untreated eye will serve as a control. When substantial eyelash growth is noted in the treated eye, patients will be instructed to decrease application to once a week. Patients will be seen every four weeks in the Department of Dermatology. In addition, eyelash growth will be assessed in the Beckman Vision Center where eyelash length will be measured, and photographs will be taken at baseline, 2 months, and 4 months. Intraocular pressure will be documented at baseline and at each visit to the Beckman Vision Center. The study will be conducted over four months.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
University of California, San Francisco | |
San Francisco, California, United States, 94117 |
Principal Investigator: | Vera H. Price, M.D. | Professor, University of California, San Francisco Department of Dermatology |
Principal Investigator: | Robert L. Stamper, M.D. | Professor, University of California, San Francisco Department of Ophthalmology |
Study ID Numbers: | H7285-26596-01 |
Study First Received: | September 13, 2005 |
Last Updated: | March 17, 2006 |
ClinicalTrials.gov Identifier: | NCT00187577 |
Health Authority: | United States: Food and Drug Administration |
Alopecia areata Eyelash growth Latanoprost Bimatoprost |
Pathological Conditions, Anatomical Alopecia Areata Alopecia areata Bimatoprost |
Skin Diseases Alopecia Latanoprost |
Hair Diseases Hypotrichosis Therapeutic Uses |
Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |